Phathom Pharmaceuticals Ownership | Who Owns Phathom Pharmaceuticals?


OverviewForecastRevenueFinancialsChartTranscripts

Phathom Pharmaceuticals Ownership Summary


Phathom Pharmaceuticals is owned by 40.75% institutional investors, 4.45% insiders, and 54.80% retail investors. Frazier life sciences management is the largest institutional shareholder, holding 17.20% of PHAT shares. Invesco OFI Global Equity is the top mutual fund, with 2.83% of its assets in Phathom Pharmaceuticals shares.

PHAT Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockPhathom Pharmaceuticals40.75%4.45%54.80%
SectorHealthcare Stocks 42.54%10.82%46.64%
IndustryBiotech Stocks 45.21%10.75%44.04%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Frazier life sciences management12.47M17.20%$146.73M
Medicxi ventures management (jersey)7.46M10.30%$87.86M
Invesco3.86M5.33%$45.49M
Blackrock2.93M5.01%$30.14M
Carlyle group3.50M4.83%$41.05M
Blackrock funding, inc. /de3.40M4.70%$40.05M
Vanguard group3.22M4.44%$37.85M
Ensign peak advisors2.50M3.45%$29.46M
Nea management company1.96M2.70%$23.07M
683 capital management1.82M2.51%$21.43M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Medicxi ventures management (jersey)7.46M11.80%$87.86M
Propel bio management552.93K6.51%$6.51M
Frazier life sciences management12.47M4.40%$146.73M
Catalys pacific1.17M3.91%$13.74M
Catalio capital management, lp1.13M2.46%$13.28M
Stepstone group lp422.08K2.34%$4.97M
Ghost tree capital600.00K1.94%$6.18M
Aigh capital management429.00K1.42%$5.05M
Nea management company1.96M1.27%$23.07M
683 capital management1.82M1.12%$21.43M

Top Buyers

HolderShares% AssetsChange
Catalio capital management, lp1.13M2.46%456.23K
Aigh capital management429.00K1.42%429.00K
Vanguard group3.22M0.00%428.26K
Summittx capital385.97K0.19%385.97K
Ameriprise financial554.59K0.00%373.74K

Top Sellers

HolderShares% AssetsChange
Jennison associates---7.04M
Checkpoint capital---2.27M
Portolan capital management---1.70M
Orbimed advisors---1.45M
Federated hermes---1.40M

New Positions

HolderShares% AssetsChangeValue
Aigh capital management429.00K1.42%429.00K$5.05M
Summittx capital385.97K0.19%385.97K$4.54M
Walleye capital290.47K0.01%290.47K$3.42M
Newedge advisors201.52K0.01%201.52K$2.23M
Jane street group107.26K0.00%107.26K$1.26B

Sold Out

HolderChange
Nelson, van denburg & campbell wealth management group-7.00
Capital performance advisors llp-29.00
Svb wealth-34.00
Rothschild investment-35.00
Amundi-42.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Sep 30, 202574-37.82%29,531,937-48.16%400.66%37-40.32%18-45.45%
Jun 30, 2025124-11.43%57,375,847-9.22%791.03%63-12.50%378.82%
Mar 31, 2025142-4.05%64,025,009-3.98%880.84%73-22.34%3534.62%
Dec 31, 202458-57.97%26,182,383-63.96%400.32%35-58.82%11-45.00%
Sep 30, 202413818.97%72,638,51228.44%1121.21%8528.79%20-

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Invesco OFI Global Equity1.98M2.83%-
Invesco Global A1.98M2.78%-
Jennison Health Sciences Equity1.78M2.56%-
Vanguard US Total Market Shares ETF1.65M2.36%280.90K
Jennison SMid Cap Core Equity1.58M2.27%-
Vanguard Total Stock Mkt Idx Inv1.55M2.22%-34.49K
Strategic Advisers U.S. Total Stock{mg}1.48M2.16%-273.72K
Strategic Advisers Small-Mid Cap1.24M1.82%278.88K
PGIM Jennison Small Company A1.21M1.73%-373.30K
Wasatch Ultra Growth1.01M1.45%-458.57K

Recent Insider Transactions


DateNameRoleActivityValue
Nov 03, 2025Breedlove Robert Charles Principal Accounting OfficerSell$7.08K
Sep 05, 2025Breedlove Robert Charles Principal Accounting OfficerSell$5.57K
Jul 16, 2025Breedlove Robert Charles Principal Accounting OfficerSell$14.15K
May 21, 2025Topper James N-Buy$14.61K
May 14, 2025Topper James N-Buy$20.92K

Insider Transactions Trends


DateBuySell
2025 Q4-1
2025 Q3-2
2025 Q281
2025 Q113
2024 Q422

PHAT Ownership FAQ


Who Owns Phathom Pharmaceuticals?

Phathom Pharmaceuticals shareholders are primarily institutional investors at 40.75%, followed by 4.45% insiders and 54.80% retail investors. The average institutional ownership in Phathom Pharmaceuticals's industry, Biotech Stocks , is 45.21%, which Phathom Pharmaceuticals falls below.

Who owns the most shares of Phathom Pharmaceuticals?

Phathom Pharmaceuticals’s largest shareholders are Frazier life sciences management (12.47M shares, 17.20%), Medicxi ventures management (jersey) (7.46M shares, 10.30%), and Invesco (3.86M shares, 5.33%). Together, they hold 32.84% of Phathom Pharmaceuticals’s total shares outstanding.

Does Blackrock own Phathom Pharmaceuticals?

Yes, BlackRock owns 5.01% of Phathom Pharmaceuticals, totaling 2.93M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 30.14M$. In the last quarter, BlackRock increased its holdings by 180.99K shares, a 6.59% change.

Who is Phathom Pharmaceuticals’s biggest shareholder by percentage of total assets invested?

Medicxi ventures management (jersey) is Phathom Pharmaceuticals’s biggest shareholder by percentage of total assets invested, with 11.80% of its assets in 7.46M Phathom Pharmaceuticals shares, valued at 87.86M$.

Who is the top mutual fund holder of Phathom Pharmaceuticals shares?

Invesco OFI Global Equity is the top mutual fund holder of Phathom Pharmaceuticals shares, with 2.83% of its total shares outstanding invested in 1.98M Phathom Pharmaceuticals shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools